{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 3 Continuous Glucose Monitoring System",
        "FreeStyle Libre 2 Flash Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care Inc.",
    "510(k) Number": "K233537",
    "Predicate Device Reference 510(k) Number(s)": [
        "K223435"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "QLG",
        "NBW"
    ],
    "Summary Letter Date": "April 23, 2024",
    "Summary Letter Received Date": "March 19, 2024",
    "Submission Date": "March 18, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor applied to back of upper arm"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 3 Sensor",
        "FreeStyle Libre 3 Plus Sensor",
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 2 Plus Sensor",
        "FreeStyle Libre 3 Reader",
        "FreeStyle Libre 2 Reader",
        "FreeStyle Libre App"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Factory calibration",
        "Bluetooth Low Energy (BLE)",
        "Near Field Communication (NFC)"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Reader",
        "App"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott FreeStyle Libre 3 and Libre 2 integrated continuous glucose monitoring systems for diabetes management",
    "Indications for Use Summary": "Indicated for the management of diabetes in persons age 2 or 4 and older, providing real-time continuous glucose monitoring, alarms, trend analysis, and autonomous communication with digitally connected devices, including automated insulin dosing systems for Plus sensor users; intended to replace blood glucose testing for diabetes treatment decisions unless otherwise indicated.",
    "fda_folder": "Clinical Chemistry"
}